ChromaDex (CDXC) Reports Break-Even Earnings for Q2

分组1 - ChromaDex reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.03, and compared to a loss of $0.03 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $22.74 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.35%, and this compares to year-ago revenues of $20.32 million [2] - ChromaDex shares have increased approximately 97.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 9.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.01 on revenues of $25.2 million, and -$0.02 on revenues of $97.28 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]